Impact of the selective A2 A R and A2 B R dual antagonist AB928/etrumadenant on CAR T cell function.
Matthias SeifertMohamed-Reda BenmebarekDaria BriukhovetskaFlorian MärklJanina DörrBruno L CadilhaJakob JobstSophia StockDavid Andreu-SanzTheo LorenziniRuth GrünmeierArman OnerHannah ObeckLina MajedDario DhoqinaManouk FeinendegenAdrian GottschlichJin ZhangUlrike SchindlerStefan EndresSebastian KoboldPublished in: British journal of cancer (2022)
Together our results suggest that combination therapy with AB928 represents a promising approach to improve adoptive cell therapy.